<code id='9C756AD161'></code><style id='9C756AD161'></style>
    • <acronym id='9C756AD161'></acronym>
      <center id='9C756AD161'><center id='9C756AD161'><tfoot id='9C756AD161'></tfoot></center><abbr id='9C756AD161'><dir id='9C756AD161'><tfoot id='9C756AD161'></tfoot><noframes id='9C756AD161'>

    • <optgroup id='9C756AD161'><strike id='9C756AD161'><sup id='9C756AD161'></sup></strike><code id='9C756AD161'></code></optgroup>
        1. <b id='9C756AD161'><label id='9C756AD161'><select id='9C756AD161'><dt id='9C756AD161'><span id='9C756AD161'></span></dt></select></label></b><u id='9C756AD161'></u>
          <i id='9C756AD161'><strike id='9C756AD161'><tt id='9C756AD161'><pre id='9C756AD161'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:267
          Adobe

          Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

          That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

          advertisement

          “It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          Research misconduct: Proposed new rules face resistance
          Research misconduct: Proposed new rules face resistance

          AdobeResearchuniversitiesarevoicingconcernsoversomeproposedchangestotheprocessforreviewingscientific

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          With competition flaring, obesity drug hits goal in liver disease study

          AdobeLONDON—AdrugindevelopmentasaweightlosstreatmentsucceededinaPhase2studyinaseriouslivercondition,